Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis

09-Apr-2008

Medical Futures Inc. has licensed MUTAFLOR(R) for the North American market. MUTAFLOR(R) is a drug used in remission maintenance of ulcerative colitis. Since its discovery in 1917, MUTAFLOR(R) has been available in the German marketplace through a subsidiary of Pharma-Zentrale GmbH, Ardeypharm GmbH. MUTAFLOR(R) has shown clinical efficacy in phase III clinical trials and has shown a perfect safety record since 1917.

"Medical Futures Inc. is excited about partnering with Pharma-Zentrale GmbH for MUTAFLOR(R)," says Dr. Par Nijhawan, Chief Medical Officer of Medical Futures Inc., who believes that MUTAFLOR(R) will help improve the options available for Ulcerative Colitis patients.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances